 Today, Clinical Reference Laboratory CRL, one of the largest privately held clinical testing laboratories in the U.S., announced that it received FDA Emergency Use Authorization EUA and is scaling up capacity for CRL Rapid ResponseTM, a saliva-based COVID-19 RT-PCR test that can be self-collected at home, work or any other setting. The test, shown in CRLs EUA studies to be more sensitive and accurate than the standard COVID-19 anterior nasal swab test, detects the presence of coronavirus in the saliva of the test taker. In addition, the test is more comfortable and easier to administer, is not technique dependent and virtually anyone can self-collect an adequate sample for testing, with test results available in 24-48 hours of receipt at CRL. CRL Rapid ResponseTM is ready for immediate commercial launch, making it the first large-scale service of its kind focused on the American workforce. Testing is critical to safely helping America get back to work, which is why CRL is offering these tests to employers in businesses, universities, government agencies, nursing homes and other organizations. CRL has already lined up several partnerships for CRL Rapid ResponseTM testing. 